Commerce Bank maintained its position in Teligent, Inc. (NASDAQ:TLGT) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,500 shares of the company’s stock at the end of the first quarter. Commerce Bank’s holdings in Teligent were worth $145,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in TLGT. Teza Capital Management LLC purchased a new position in Teligent during the first quarter valued at approximately $116,000. Round Table Services LLC increased its stake in Teligent by 46.6% in the first quarter. Round Table Services LLC now owns 19,478 shares of the company’s stock worth $152,000 after buying an additional 6,191 shares during the last quarter. UBS Asset Management Americas Inc. bought a new stake in Teligent during the first quarter worth $170,000. Cutler Group LP increased its stake in Teligent by 217.6% in the first quarter. Cutler Group LP now owns 23,923 shares of the company’s stock worth $186,000 after buying an additional 16,391 shares during the last quarter. Finally, Zacks Investment Management bought a new stake in Teligent during the third quarter worth $198,000. 63.82% of the stock is currently owned by hedge funds and other institutional investors.
Teligent, Inc. (NASDAQ TLGT) traded down 0.12% during midday trading on Friday, hitting $8.63. 238,433 shares of the stock were exchanged. The company’s 50 day moving average is $8.62 and its 200 day moving average is $7.60. Teligent, Inc. has a 1-year low of $5.74 and a 1-year high of $9.20. The company’s market capitalization is $459.34 million.
Separately, Zacks Investment Research downgraded shares of Teligent from a “buy” rating to a “hold” rating in a research note on Saturday, February 18th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $9.67.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.